Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255060, C544S405000, C544S406000
Reexamination Certificate
active
10798198
ABSTRACT:
Novel pyrazine compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-β signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
REFERENCES:
patent: 3119742 (1964-01-01), Heimlich et al.
patent: 3492397 (1970-01-01), Peters et al.
patent: 3538214 (1970-11-01), Polli et al.
patent: 4060598 (1977-11-01), Groppenbächer et al.
patent: 4173626 (1979-11-01), Dempski et al.
patent: 1156045 (2001-11-01), None
patent: WO0248152 (2002-06-01), None
patent: WO0262776 (2002-08-01), None
patent: WO0262787 (2002-08-01), None
patent: WO0304472 (2003-01-01), None
patent: WO0304475 (2003-01-01), None
patent: WO0393297 (2003-11-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
De Meester, J.W.G., et al., “Synthesis of 3-Alkyl-6-Phenyl-4(3H)-pteridinones and their 8-Oxides. Potential Substrates of Xanthine Oxidase”, J. Heterocyclic Chem. vol. 24, No. 4, pp. 1109-1116 (1987).
Laping, N.J., et al., “Inhibition of Transforming Growth Factor (TGF)-β1-induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542”, Molecular Pharmacology, vol. 62, No. 1, pp. 58-64 (2002).
Ashbrook Charles W.
Baude Eric J.
Goodman Rosanne
Pfizer Inc.
Tucker Zachary C.
LandOfFree
Pyrazine compounds as transforming growth factor (TGF)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazine compounds as transforming growth factor (TGF)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazine compounds as transforming growth factor (TGF)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3762195